Compatibility and Stability of 5-HT3 Receptor Antagonists: A Pharmacology Review

Viki Longfield

ONF 2002, 29(10), 1469-1482. DOI: 10.1188/02.ONF.1469-1482

Purpose/Objectives: To compare stability and compatibility among the 5-HT3 antiemetics in multidrug cytotoxic regimens.

Data Sources: Published articles, product-prescribing information, and direct communication with manufacturers.

Data Synthesis: Stability and compatibility of ondansetron and granisetron with a variety of other agents used in the oncology setting generally are similar. Granisetron is compatible with all tested Y-site drugs; ondansetron is not compatible with amsacrine or fluorouracil. Information for dolasetron is not as readily available; therefore, comparisons are difficult to make.

Conclusion: Although 5-HT3 receptor antagonists have made a significant impact in decreasing severe emesis, administration of complex regimens can be confusing at best for nurses because of the lack of compatibility data. By partnering with pharmacists, nurses can develop administration guidelines to minimize complications and improve outcomes.

Implications for Nursing: To maximize patients' outcomes, oncology nurses must be knowledgeable about stability and compatibility of complex multidrug regimens that include the commonly used 5-HT3 receptor antagonist antiemetics.

Jump to a section

    References

    Aventis Pharmaceuticals. (2002). Anzemet® [Package insert]. Kansas City, MO: Author.

    Bergman, H.D. (1977). Incompatibilities in large volume parenterals. Drug Intelligence and Clinical Pharmacy, 11, 345-360.

    Cohen, M.H., Johnston-Early, A., Hood, M.A., McKenzie, M., Citron, M.L., Jaffe, N., et al. (1985). Drug precipitation within i.v. tubing: A potential hazard of chemotherapy administration. Cancer Treatment Reports, 69, 1325-1326.

    Craig, J.B., & Powell, B.L. (1987). The management of nausea and vomiting in clinical oncology. American Journal of the Medical Sciences, 293, 34-44.

    Eisenberg, S. (1997). Intravenous drug compatibility: A challenge for the oncology nurse. Oncology Nursing Forum, 24, 859-869.

    Evrard, B., Ceccato, A., Gaspard, O., Delattre, L., & Delporte, J.P. (1997). Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection. American Journal of Health-System Pharmacy, 54, 1065-1068.

    Gordon, E.L. (1986). IV medication compatibility chart. Critical Care Nurse, 6(4), 82-83.

    Hagan, R.L., Mallett, M.S., & Fox, J.L. (1996). Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. American Journal of Health-System Pharmacy, 53, 1431-1435.

    Hourcade, F., Sautou-Miranda, V., Normand, B., Laugier, M., Picq, F., & Chopineau, J. (1997). Compatibility of granisetron towards glass and plastics and its stability under various storage conditions. International Journal of Pharmaceutics, 154, 95-102.

    Jarosinski, P.F., & Hirschfeld, S. (1991). Precipitation of ondansetron in alkaline solutions. New England Journal of Medicine, 325, 1315-1316.

    Johnson, M.H., Moroney, C.E., & Gay, C.F. (1997). Relieving nausea and vomiting in patients with cancer: A treatment algorithm. Oncology Nursing Forum, 24, 51-57.

    Leissing, N.C., Story, K.O., & Zaske, D. (1989). Inline fluid dynamics in piggyback and manifold drug delivery systems. American Journal of Hospital Pharmacy, 46, 89-97.

    Love, R.R., Leventhal, H., Easterling, D.V., & Nerenz, D.R. (1989). Side effects and emotional distress during cancer chemotherapy. Cancer, 63, 604-612.

    Mayron, D., & Gennaro, A.R. (1996). Stability and compatibility of granisetron hydrochloride in i.v. solutions and oral liquids and during simulated Y-site injection with selected drugs. American Journal of Health-System Pharmacy, 53, 294-304.

    McGuire, T.R., Narducci, W.A., & Fox, J.L. (1993). Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. American Journal of Hospital Pharmacy, 50, 1410-1414.

    McKenry, L.M., & Salerno, E. (1998). Pharmacology in nursing (20th ed., pp. 79-80). St. Louis, MO: Mosby-Year Book.

    Newton, D.W. (1978). Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures. American Journal of Hospital Pharmacy, 35, 1213-1222.

    Nightengale, B.S., & Mauch, R.P. (1998). A pharmacoeconomic review of granisetron and ondansetron in the prophylaxis of chemotherapy-induced nausea and vomiting. Pharmacy and Therapeutics, 23, 119-130.

    Pinguet, F., Rouanet, P., Martel, P., Fabro, M., Salabert, D., & Astre, C. (1995). Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. Journal of Pharmaceutical Sciences, 84, 267-268.

    Rakel, R.E. (Ed.). (1999). Conn's current therapy 2000. Philadelphia: Saunders.

    Roche Pharmaceuticals. (2002). Kytril® [Package insert]. Nutley, NJ: Author.

    Salamone, F.R., & Muller, R.J. (1990). Intravenous admixture compatibility of cancer chemotherapeutic agents. Hospital Pharmacy, 25, 567-570.

    San Angel, F. (1993). An overview of ondansetron for chemotherapy-induced nausea and emesis. Journal of Intravenous Nursing, 16, 84-89.

    Stella, V.J. (1986). Chemical and physical bases determining the instability and incompatibility of formulated injectable drugs. Journal of Parenteral Science and Technology, 40, 142-163.

    Stewart, J.T., Warren, F.W., King, D.T., & Fox, J.L. (1996). Stability of ondansetron hydrochloride and five antineoplastic medications. American Journal of Health-System Pharmacy, 53, 1297-1300.

    Stewart, J.T., Warren, F.W., King, D.T., Venkateshwaran, T.G., Ponder, G.W., & Fox, J.L. (1997). Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. American Journal of Health-System Pharmacy, 54, 915-920.

    Trissel, L.A. (1993). Blocking i.v. drug incompatibilities. Nursing, 23(6), 74.

    Trissel, L.A. (1998). Handbook on injectable drugs (10th ed.). Bethesda, MD: American Society of Health-System Pharmacists.

    Trissel, L.A., Gilbert, D.L., & Martinez, J.F. (1997a). Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 54, 2708-2713.

    Trissel, L.A., Gilbert, D.L., & Martinez, J.F. (1997b). Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 54, 56-60.

    Trissel, L.A., Gilbert, D.L., Martinez, J.F., Baker, M.B., Walter, W.V., & Mirtallo, J.M. (1999). Compatibility of medications with 3-in-1 parenteral nutrition admixtures. Journal of Parenteral Nutrition, 23(2), 67-74.

    Trissel, L.A., Gilbert, D.L., & Williams, K.Y. (1999). Compatibility screening of gatifloxacin during simulated Y-site administration with other drugs. Hospital Pharmacy, 34, 1409-1416.

    Trissel, L.A., & Martinez, J.F. (1995). Compatibility of granisetron hydrochloride with selected alkaline drugs. American Journal of Health-System Pharmacy, 52, 208.

    Trissel, L.A., Martinez, J.F., & Gilbert, D.L. (1996). Screening cladribine for Y-site physical compatibility with selected drugs. Hospital Pharmacy, 31, 1425-1428.

    Trissel, L.A., Tramonte, S.M., & Grilley, B.J. (1991). Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. American Journal of Hospital Pharmacy, 48, 988-993.

    Vyas, H.M., Baptista, R.J., Mitrano, F.P., & Sesin, G.P. (1987). Drug stability guidelines for a continuous infusion chemotherapy program. Hospital Pharmacy, 22, 685-687.

    Whitman, M. (1995). The push is on. Delivering medications safely by IV bolus. Nursing, 25(8), 52-54.

    Wong, A.H., Law, S., Walker, S.E., & Bowles, S.K. (2000). Concentration-dependent compatibility and stability of dexamethasone and midazolam. Canadian Journal of Hospital Pharmacy, 53(1), 24-31.